

The Board of Directors' of Infant Bacterial Therapeutics AB (publ) report in accordance with Chapter 13 Section 6 of the Swedish Companies Act

In addition to the information announced by Infant Bacterial Therapeutics AB (publ) through press releases up until the day of this report, principally the interim report for the first quarter 2023, which was announced on May 8, 2023, no events of material significance for the company's financial position have occurred since the annual report for the financial year 2022 was submitted. All information is available on Infant Bacterial Therapeutics AB's (publ) website <https://ibtherapeutics.com> under Investors & Media – Press Releases.

Stockholm, May 16, 2023

Infant Bacterial Therapeutics AB (publ)
The Board of Directors